Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 09:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting

SOMERVILLE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and...
October 24, 2024 06:30 ET | Source: Tessera Therapeutics

Tessera Therapeutics Presents New Preclinical Data in In Vivo AATD and SCD Programs at the 31st Annual Congress of the European Society of Gene and Cell Therapy

A single intravenous administration of Gene Writer™ resulted in an estimated 79% hepatocyte genomic editing with an average of 84% of mRNA transcripts containing the edited sequence in non-human...
June 20, 2024 07:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics Presents Non-Human Primate (NHP) Data in Alpha-1 Antitrypsin Deficiency (AATD) Program at the Federation of American Societies for Experimental Biology Meeting on Genome Engineering

First-time demonstration in NHPs of therapeutically relevant levels of editing at the SERPINA1 locus responsible for AATD with a single dose of RNA Gene WriterDr. Cecilia Cotta-Ramusino, Tessera’s...
May 10, 2024 06:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting

Gene Writing™ platform demonstrates highly efficient in vivo correction of mutation responsible for alpha-1 antitrypsin deficiency (AATD) to wild-typeCombination of proprietary lipid nanoparticle...
April 22, 2024 16:30 ET | Source: Tessera Therapeutics

Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting

SOMERVILLE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and...
May 19, 2023 06:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting

RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD) and sickle cell...
May 02, 2023 16:30 ET | Source: Tessera Therapeutics

Tessera Therapeutics to Present New Data Showcasing the Broad Potential of its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 26th Annual Meeting

SOMERVILLE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that it will...
April 18, 2023 08:00 ET | Source: Tessera Therapeutics

Tessera Therapeutics Names Cynthia M. Patton as General Counsel and Secretary

SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, announced the appointment...
January 09, 2023 08:30 ET | Source: Tessera Therapeutics

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates

RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human primates following a single administrationRNA Gene Writing™ platform...